Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 11%

Bulls say

Arvinas is leading the way in targeted protein degraders and is well-positioned in the biotechnology industry. With a strong clinical development program and key partnerships with big players like Pfizer and Novartis, they have the potential for significant commercial success. Furthermore, the company's leadership in the LRRK2 pathway and strong biomarker data in their clinical trials showcase their potential for groundbreaking treatments in the future. Overall, their innovative approach to protein degradation and promising results make them a strong buy with potential for long-term growth. However, as with any biotech company, there are standard industry risks that investors should be aware of.

Bears say

Arvinas is a clinical-stage biotechnology company with a focus on developing protein degradation therapeutics for oncology and neurology-related diseases. Despite the potential of its PROteolysis TArgeting Chimera (PROTAC) technology, the company faces challenges in bringing its promising pipeline candidates to market, with only ARV-471 in Phase 2 clinical trials. Additionally, with limited revenue and high research and development expenses, Arvinas may struggle to sustain its operations in the long term.

Arvinas Inc (ARVN) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 11% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 9 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.